Earnings Per Share (EPS) of $0.37, significantly surpassing the estimated $0.18.Revenue of approximately $228.9 million, exceeding the estimated $205.8 million.Low debt-to-equity ratio of 0.06 and a current ratio of 3.43, indicating strong financial health.Varex Imaging Corporation (NASDAQ:VREX), a key player in the medical products industry, specializes in imaging components crucial for medical diagnostics. Competing in the medical imaging sector, Varex strives to deliver innovative solutions and has recen ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - VAREX IMAGING reported revenue of $228.9 million for the quarter ended September 2025, reflecting an 11.3% increase year-over-year and surpassing the Zacks Consensus Estimate of $220.45 million by 3.83% [1] - The company's EPS for the quarter was $0.37, significantly higher than the $0.19 reported in the same quarter last year, and exceeded the consensus EPS estimate of $0.18 by 105.56% [1] Revenue Breakdown - Industrial revenue reached $76.8 million, exceeding the average estimate of $65.39 million by analysts, marking a 25.3% increase compared to the previous year [4] - Medical revenue was reported at $152.1 million, slightly below the average estimate of $155.08 million, but still showing a year-over-year increase of 5.3% [4] Profit Metrics - Gross profit from Industrial operations was $29.8 million, surpassing the average estimate of $22.05 million [4] - Gross profit from Medical operations was $48 million, which was below the average estimate of $49.24 million [4] Stock Performance - Over the past month, VAREX IMAGING shares have returned -1.7%, contrasting with a +0.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]

Company Performance - VAREX IMAGING reported quarterly earnings of $0.37 per share, exceeding the Zacks Consensus Estimate of $0.18 per share, and up from $0.19 per share a year ago, representing an earnings surprise of +105.56% [1] - The company posted revenues of $228.9 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 3.83%, compared to year-ago revenues of $205.7 million [2] - Over the last four quarters, VAREX IMAGING has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance - VAREX IMAGING shares have declined approximately 21.7% since the beginning of the year, while the S&P 500 has gained 13.4% [3] - The current Zacks Rank for VAREX IMAGING is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.21 on revenues of $207.65 million, and for the current fiscal year, it is $0.97 on revenues of $861.55 million [7] - The outlook for the Medical - Products industry, to which VAREX IMAGING belongs, is currently in the bottom 30% of Zacks industries, which may impact the stock's performance [8]

Varex Imaging (NasdaqGS:VREX) Q4 2025 Earnings Call November 18, 2025 05:00 PM ET Company ParticipantsSam Maheshwari - CFOSunny Sanyal - President and CEOChris Belfiore - Director of Investor RelationsConference Call ParticipantsLarry Solow - Managing Director and Healthcare AnalystJim Sidoti - Research Analyst of Medical DevicesAnderson Schock - MedTech Equity Research AnalystSuraj Kalia - Managing Director and Senior Analyst of Medical Technology and DevicesOperatorGreetings and welcome to the Varex Fourt ...

Varex Imaging (NasdaqGS:VREX) Q4 2025 Earnings Call November 18, 2025 05:00 PM ET Company ParticipantsSam Maheshwari - CFOSunny Sanyal - President and CEOChris Belfiore - Director of Investor RelationsConference Call ParticipantsLarry Solow - Managing Director and Healthcare AnalystJim Sidoti - Research Analyst of Medical DevicesAnderson Schock - MedTech Equity Research AnalystSuraj Kalia - Managing Director and Senior Analyst of Medical Technology and DevicesOperatorGreetings and welcome to the Varex Fourt ...

Financial Data and Key Metrics Changes - The company reported Q4 revenue of $229 million, an 11% increase year over year, and at the high end of guidance [5][12] - Non-GAAP gross margin for Q4 was 34%, up 130 basis points from the same quarter last year [6][15] - Non-GAAP earnings per share for Q4 was $0.37, up $0.21 compared to last year [6][18] - For the full fiscal year, total revenue was $845 million, a 4% increase compared to fiscal 2024 [6][12] - Non-GAAP EBITDA for the year was $122 million, up $33 million from $89 million last year [6][19] Business Line Data and Key Metrics Changes - Medical segment revenue increased by 5% year over year to $152 million in Q4, while industrial segment revenue surged by 25% to $77 million [5][12] - For the full year, medical revenue was $593 million, a 2% increase, and industrial revenue was $252 million, a 10% increase [6][12] - The industrial segment achieved its highest revenue quarter ever at $77 million [5][12] Market Data and Key Metrics Changes - Revenue from the Americas grew by 9%, EMEA rose by 16%, and APAC increased by 8% year over year [13] - Sales volume to China remained steady, contributing 14% of total revenues, despite tariff challenges [13][18] Company Strategy and Development Direction - The company is focusing on growth initiatives, including innovative technologies like photon counting for CT and expanding production in India [9][25] - The strategy includes strengthening geopolitical resiliency through supply chain and manufacturing regionalization [22][24] - The company plans to invest in R&D to maintain a competitive edge and target growth markets such as India, South Asia, and Latin America [24][25] Management's Comments on Operating Environment and Future Outlook - Management noted a challenging start to fiscal 2025 due to global tariff situations, but customer ordering patterns normalized as the situation stabilized [22] - Customers in China are projecting stronger orders for 2026 compared to previous years, driven by demand for value-tier and mid-tier CT systems [22][24] - The company expects gradual growth throughout fiscal 2026, with medical business anticipated to grow, while China is modeled to be stable [42][44] Other Important Information - The company ended the year with $155 million in cash, down from $213 million the previous year, primarily due to debt reduction [6][19] - The company reported a net cash flow from operations of $8 million in Q4 [19] Q&A Session Summary Question: Can you split the top 10 customers' contribution between medical and industrial? - The company does not break out the contribution between medical and industrial due to commercial reasons, but top 10 customers generally account for 50%-55% of sales [33] Question: Is there a structural shift in the medical and industrial segments? - Industrial sales are growing and approaching 30% of overall sales, while medical segment volatility is influenced by geopolitical factors [35] Question: Any implications from GE or Siemens divesting their China business? - The majority of business in China comes through Chinese OEMs, so these announcements do not have significant implications for the company [38] Question: Can you provide a high-level outlook for the full year? - The demand environment looks solid, with expectations for growth in both medical and industrial segments, though China is modeled to be stable [42][44] Question: What is the impact of tariffs on gross margin? - Tariffs are impacting gross margin by approximately 100 to 150 basis points, but rerouting supply chains may help mitigate this in the future [83]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

11/18/2025 1 Making the Invisible Visible Q4 FY25 Earnings Presentation November 18, 2025 While forward-looking statements are based on assumptions and analyses made by management of Varex that it believes to be reasonable under the circumstances, whether actual results and developments will meet such expectations depends on a number of risks and uncertainties which could cause actual results, performance, and financial condition to differ materially from such expectations. Such risks and uncertainties incl ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...